Abstract:There is an urgent need for the introduction of novel and better (i.e., improved risk-benefit profile) compounds for the treatment of major psychiatric disorders, in particular mood and psychotic disorders. However, despite increased societal awareness and a rising public and professional demand for such agents from patients and physicians, the pharmaceutical industry continues to close down its psychopharmacology research facilities in reaction to the lack of success with the search for new psychotropics. It is high time to stop this untoward trend and explore "new" lines of investigation to solve the current crisis in psychopharmacological research. In line with the prevailing molecular view in drug research in general, also in psychopharmacology mechanistic explanations for drug effects are "traditionally" looked for at the level of molecular targets, like receptors and transporters. Also, more recent approaches, although using so-called systems- and function-based approaches to model the multidimensional characteristics of psychiatric disorders and psychotropic drug action, still emphasize this search strategy for new therapeutic leads by identification of single molecules or molecular pathways. This "psychomolecular gaze" overlooks and disregards the fact that psychotropic agents usually are highly hydrophobic and amphipathic/amphiphilic agents that, in addition to their interaction with membrane-bound proteins in the form of e.g. receptors or transporters, also interact strongly with the lipid component of cellular membranes. Here we suggest to develop a program of systematic, whole-cell level based, investigation into the role of these physical-chemical cellular membrane interactions in the therapeutic action of known psychotherapeutics. This complementary yet conceptually different approach, in our opinion, will complement drug development in psychopharmacology and thereby assist in overcoming the current crisis. In this way the "old" physical theory of drug action, which antedates the current, primary molecular, paradigm may offer "new" options for lead discovery in psychopharmacological research.

Introduction to the Special Issue: Experimental Therapeutics in Clinical Child and Adolescent Psychology: Identifying Mechanisms and Moving the Needle

A History of Child and Adolescent Treatment Through a Distillation Lens: Looking Back to Move Forward

Ethical considerations in clinical training, care and research in psychopharmacology

Effective Use of Animal Models for Therapeutic Development in Psychiatric and Substance Use Disorders

Integrating contextual behavioral science with research on psychedelic assisted therapy: Introduction to the special section

Mechanisms linking childhood adversity with psychopathology: Learning as an intervention target

Mechanism-Focused Randomized Controlled Trials in Youths: Another Step Uphill

Toward Dynamic Adaptation of Psychological Interventions for Child and Adolescent Development and Mental Health

Developing Treatments for Antisocial Behavior Among Children: Controlled Trials and Uncontrolled Tribulations

Precision Psychiatry Implementation in Child and Adolescent Psychiatric Clinical Practice: Opportunities and Challenges

State of the Science in Behavior Therapy: Taking Stock and Looking Forward

Major Problems in Clinical Psychological Science and How to Address them. Introducing a Multimodal Dynamical Network Approach

Preclinical animal models and assays of neuropsychiatric disorders: Old problems and New Vistas - introduction to the special issue

Introduction to the Special Issue: Novel Insights into the Externalizing Psychopathology Spectrum in Childhood and Adolescence from Intensive Longitudinal Data

Pragmatic clinical trials to advance research in children and adolescents with eating disorders

Solving the crisis in psychopharmacological research: Cellular-membrane(s) pharmacology to the rescue?

Mechanism engagement as a potential evidence-based approach to personalized treatment termination

A Case for Translation From the Clinic to the Laboratory

Promising avenues of therapeutics for bipolar illness

New Horizons in Pediatric Psychopharmacology

Behavioral Activation as a Principle-Based Treatment: Developments from a Multi-Site Collaboration to Advance Adolescent Depression Treatment